

(51) International Patent Classification:
Not classified(21) International Application Number:
PCT/US2024/030085(22) International Filing Date:
17 May 2024 (17.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/503,387	19 May 2023 (19.05.2023)	US
63/535,991	31 August 2023 (31.08.2023)	US
63/606,521	05 December 2023 (05.12.2023)	US
63/558,052	26 February 2024 (26.02.2024)	US

(71) Applicant: SOLVE THERAPEUTICS, INC. [US/US];
11045 Roselle Street, Suite 130, San Diego, California
92121 (US).(72) Inventors: LANNUTTI, Brian; 11045 Roselle Street,
Suite 130, San Diego, California 92121 (US). WATKINS,
Jeff; 11045 Roselle Street, Suite 130, San Diego, California
92121 (US). JESSEN, Katti; 11045 Roselle Street, Suite
130, San Diego, California 92121 (US).(74) Agent: MARTINEZ, Jose et al.; WILSON SONSINI
GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO
ALTO, California 94304-1050 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CONJUGATES AND USES THEREOF



(57) Abstract: Provided herein is a Drug-Linker of Formula (X): (For-
mula (X)) or a pharmaceutically acceptable salt thereof, wherein the
variables of Formula (X) are as defined in the application. Such com-
pounds can be useful as anti-cancer agents.

FIG. 8

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*